Cargando…
T-cell agonists in cancer immunotherapy
Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537335/ https://www.ncbi.nlm.nih.gov/pubmed/33020242 http://dx.doi.org/10.1136/jitc-2020-000966 |
_version_ | 1783590654482317312 |
---|---|
author | Choi, Yeonjoo Shi, Yaoyao Haymaker, Cara L Naing, Aung Ciliberto, Gennaro Hajjar, Joud |
author_facet | Choi, Yeonjoo Shi, Yaoyao Haymaker, Cara L Naing, Aung Ciliberto, Gennaro Hajjar, Joud |
author_sort | Choi, Yeonjoo |
collection | PubMed |
description | Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials. |
format | Online Article Text |
id | pubmed-7537335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-75373352020-10-07 T-cell agonists in cancer immunotherapy Choi, Yeonjoo Shi, Yaoyao Haymaker, Cara L Naing, Aung Ciliberto, Gennaro Hajjar, Joud J Immunother Cancer Review Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials. BMJ Publishing Group 2020-10-05 /pmc/articles/PMC7537335/ /pubmed/33020242 http://dx.doi.org/10.1136/jitc-2020-000966 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Choi, Yeonjoo Shi, Yaoyao Haymaker, Cara L Naing, Aung Ciliberto, Gennaro Hajjar, Joud T-cell agonists in cancer immunotherapy |
title | T-cell agonists in cancer immunotherapy |
title_full | T-cell agonists in cancer immunotherapy |
title_fullStr | T-cell agonists in cancer immunotherapy |
title_full_unstemmed | T-cell agonists in cancer immunotherapy |
title_short | T-cell agonists in cancer immunotherapy |
title_sort | t-cell agonists in cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537335/ https://www.ncbi.nlm.nih.gov/pubmed/33020242 http://dx.doi.org/10.1136/jitc-2020-000966 |
work_keys_str_mv | AT choiyeonjoo tcellagonistsincancerimmunotherapy AT shiyaoyao tcellagonistsincancerimmunotherapy AT haymakercaral tcellagonistsincancerimmunotherapy AT naingaung tcellagonistsincancerimmunotherapy AT cilibertogennaro tcellagonistsincancerimmunotherapy AT hajjarjoud tcellagonistsincancerimmunotherapy |